MSC Therapy for Pulmonary Fibrosis: 2026 Preclinical and Clinical Evidence Review

A medical review of MSC-based and MSC-derived EV therapies for idiopathic pulmonary fibrosis, covering meta-analysis data, immune-cloaked cell engineering, nebulized exosome delivery, gut-lung axis mechanisms, and active clinical trials.